These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

560 related items for PubMed ID: 24894769

  • 21. Mixed histiocytic neoplasms: A multicentre series revealing diverse somatic mutations and responses to targeted therapy.
    Friedman JS, Durham BH, Reiner AS, Yabe M, Petrova-Drus K, Dogan A, Pulitzer M, Busam KJ, Francis JH, Rampal RK, Ulaner GA, Reddy R, Yeh R, Hatzoglou V, Lacouture ME, Rotemberg V, Mazor RD, Hershkovitz-Rokah O, Shpilberg O, Goyal G, Go RS, Abeykoon JP, Rech K, Morlote D, Fidai S, Gannamani V, Zia M, Abdel-Wahab O, Panageas KS, Rosenblum MK, Diamond EL.
    Br J Haematol; 2024 Jul; 205(1):127-137. PubMed ID: 38613141
    [Abstract] [Full Text] [Related]

  • 22. Hypoalphalipoproteinemia and BRAFV600E Mutation Are Major Predictors of Aortic Infiltration in the Erdheim-Chester Disease.
    Cohen-Aubart F, Guerin M, Poupel L, Cluzel P, Saint-Charles F, Charlotte F, Arsafi Y, Emile JF, Frisdal E, Le Goff C, Donadieu J, Amoura Z, Lesnik P, Haroche J, Le Goff W.
    Arterioscler Thromb Vasc Biol; 2018 Aug; 38(8):1913-1925. PubMed ID: 29930009
    [Abstract] [Full Text] [Related]

  • 23. Evaluation of clinicopathologic characteristics and the BRAF V600E mutation in Erdheim-Chester disease among Chinese adults.
    Cao XX, Sun J, Li J, Zhong DR, Niu N, Duan MH, Liang ZY, Zhou DB.
    Ann Hematol; 2016 Apr; 95(5):745-50. PubMed ID: 26858028
    [Abstract] [Full Text] [Related]

  • 24. Long-term outcome and prognosis of mixed histiocytosis (Erdheim-Chester disease and Langerhans Cell Histiocytosis).
    Pegoraro F, Papo M, Cohen-Aubart F, Peyronel F, Lugli G, Trambusti I, Baulier G, de Menthon M, Le Scornet T, Oziol E, Ferreira-Maldent N, Hermine O, Faucher B, Koschel D, Straetmans N, Abisror N, Terrier B, Lifermann F, Razanamahery J, Allenbach Y, Keraen J, Bulifon S, Hervier B, Buccoliero A, Charlotte F, Monzani Q, Boussouar S, Shor N, Tondo A, Barete S, Idbaih A, Tazi A, Sieni E, Amoura Z, Emile JF, Vaglio A, Haroche J.
    EClinicalMedicine; 2024 Jul; 73():102658. PubMed ID: 38841707
    [Abstract] [Full Text] [Related]

  • 25. [Erdheim-Chester disease (ECD), an inflammatory myeloid neoplasia].
    Haroche J, Papo M, Cohen-Aubart F, Charlotte F, Maksud P, Grenier PA, Cluzel P, Mathian A, Emile JF, Amoura Z.
    Presse Med; 2017 Jan; 46(1):96-106. PubMed ID: 27234902
    [Abstract] [Full Text] [Related]

  • 26. Biological and clinical significance of somatic mutations in Langerhans cell histiocytosis and related histiocytic neoplastic disorders.
    Allen CE, Parsons DW.
    Hematology Am Soc Hematol Educ Program; 2015 Jan; 2015():559-64. PubMed ID: 26637772
    [Abstract] [Full Text] [Related]

  • 27. [Central nervous system disorders secondary to histiocytoses: neurodegeneration with potential for improvement].
    Morimoto A, Sakamoto K, Kudo K, Shioda Y.
    Rinsho Shinkeigaku; 2024 Feb 23; 64(2):85-92. PubMed ID: 38281751
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Langerhans cell histiocytosis and Erdheim-Chester disease overlap syndrome with bone marrow involvement and type 2 diabetes mellitus.
    Chen M, Ding C, Lu T, Niu N, Han B.
    Ann Hematol; 2018 Jan 23; 97(1):189-192. PubMed ID: 28889238
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. BRAF V600E Mutation: A Significant Biomarker for Prediction of Disease Relapse in Pediatric Langerhans Cell Histiocytosis.
    Ozer E, Sevinc A, Ince D, Yuzuguldu R, Olgun N.
    Pediatr Dev Pathol; 2019 Oct 23; 22(5):449-455. PubMed ID: 31072207
    [Abstract] [Full Text] [Related]

  • 33. BRAF V600E mutations are not an oncogenic driver of solitary xanthogranuloma and reticulohistiocytoma: Testing may be useful in screening for Erdheim-Chester disease.
    Hoyt BS, Yan S, Linos KD, Momtahen S, Sriharan A, Tran TN, Tsongalis GJ, O'Meara RR, Green DC, LeBlanc RE.
    Exp Mol Pathol; 2019 Dec 23; 111():104320. PubMed ID: 31639332
    [Abstract] [Full Text] [Related]

  • 34. Association between clinicopathologic characteristics and BRAFV600E expression in Chinese patients with Langerhans cell histiocytosis.
    Huang H, Lu T, Sun Y, Li S, Li J, Xu K, Feng RE, Xu ZJ.
    Thorac Cancer; 2019 Oct 23; 10(10):1984-1992. PubMed ID: 31441596
    [Abstract] [Full Text] [Related]

  • 35. Molecular and clinicopathologic characterization of pediatric histiocytoses.
    Hélias-Rodzewicz Z, Donadieu J, Terrones N, Barkaoui MA, Lambilliotte A, Moshous D, Thomas C, Azarnoush S, Pasquet M, Mansuy L, Aladjidi N, Jeziorski E, Marec-Berard P, Gilibert-Yvert M, Spiegel A, Saultier P, Pellier I, Pagnier A, Pertuisel S, Poiree M, Bodet D, Millot F, Isfan F, Stephan JL, Leruste A, Rigaud C, Filhon B, Carausu L, Reguerre Y, Kieffer I, Brichard B, Ben Jannet R, Bakari M, Idbaih A, Bodemer C, Cohen-Aubart F, Haroche J, Tazi A, Boudjemaa S, Fraitag S, Emile JF, Heritier S, French Histiocytosis Study Group.
    Am J Hematol; 2023 Jul 23; 98(7):1058-1069. PubMed ID: 37115038
    [Abstract] [Full Text] [Related]

  • 36. Molecular Profiling of Tumor Tissue and Plasma Cell-Free DNA from Patients with Non-Langerhans Cell Histiocytosis.
    Janku F, Diamond EL, Goodman AM, Raghavan VK, Barnes TG, Kato S, Abdel-Wahab O, Durham BH, Meric-Bernstam F, Kurzrock R.
    Mol Cancer Ther; 2019 Jun 23; 18(6):1149-1157. PubMed ID: 31015311
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Dabrafenib and steroids for the treatment of Erdheim-Chester disease with extensive CNS involvement: a case report.
    Yuen CA, Bao S, Aung MS, Shishodia R, Kong XT.
    Per Med; 2024 Jun 23; 21(2):71-78. PubMed ID: 38275171
    [Abstract] [Full Text] [Related]

  • 40. Biological and therapeutic implications of the BRAF pathway in histiocytic disorders.
    Arceci RJ.
    Am Soc Clin Oncol Educ Book; 2014 Jun 23; ():e441-5. PubMed ID: 24857137
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 28.